Published in J Vis Exp on May 14, 2012
The potential of biologics for the treatment of asthma. Nat Rev Drug Discov (2012) 1.11
Overview of vertebrate animal models of fungal infection. J Immunol Methods (2014) 0.77
Complement mediators: key regulators of airway tissue remodeling in asthma. J Transl Med (2015) 0.75
Loki zupa (Luooukezupa) decoction reduced airway inflammation in an OVA-induced asthma mouse model. Chin Med (2016) 0.75
Redistribution of adrenomedullary nicotinic acetylcholine receptor subunits and the effect on circulating epinephrine levels in a murine model of acute asthma. Int J Mol Med (2016) 0.75
Clarithromycin might attenuate the airway inflammation of smoke-exposed asthmatic mice via affecting HDAC2. J Thorac Dis (2015) 0.75
Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med (1997) 7.12
The global burden of asthma. Chest (2006) 5.74
The mouse trap: It still yields few answers in asthma. Am J Respir Crit Care Med (2006) 2.68
Pulmonary responses to bronchoconstrictor agonists in the mouse. J Appl Physiol (1985) (1988) 2.64
Mouse models of allergic asthma: acute and chronic allergen challenge. Dis Model Mech (2008) 1.86
Ovalbumin-sensitized mice are good models for airway hyperresponsiveness but not acute physiological responses to allergen inhalation. Clin Exp Allergy (2007) 1.79
Lung inflammation and epithelial changes in a murine model of atopic asthma. Am J Respir Cell Mol Biol (1996) 1.75
Do mouse models of allergic asthma mimic clinical disease? Int Arch Allergy Immunol (2004) 1.49
Mouse models of asthma: a comparison between C57BL/6 and BALB/c strains regarding bronchial responsiveness, inflammation, and cytokine production. Inflamm Res (2009) 1.42
Animal models of asthma. Am J Physiol Lung Cell Mol Physiol (2009) 1.31
Effect of somatic growth, strain, and sex on double-chamber plethysmographic respiratory function values in healthy mice. J Appl Physiol (1985) (2002) 1.18
Invasive and noninvasive lung function measurements in rodents. J Pharmacol Toxicol Methods (2006) 1.15
Mouse models of airway responsiveness: physiological basis of observed outcomes and analysis of selected examples using these outcome indicators. Annu Rev Physiol (1999) 1.15
Comparison of allergic lung disease in three mouse strains after systemic or mucosal sensitization with ovalbumin antigen. Immunogenetics (2009) 1.06
Non-surgical intratracheal instillation of mice with analysis of lungs and lung draining lymph nodes by flow cytometry. J Vis Exp (2011) 1.03
Pro: mice are a good model of human airway disease. Am J Respir Crit Care Med (2002) 0.95
Measurement of bronchoconstriction using whole-body plethysmograph: comparison of freely moving versus restrained guinea pigs. J Pharmacol Toxicol Methods (1998) 0.93
Comparison of aerosol and intranasal challenge in a mouse model of allergic airway inflammation and hyperresponsiveness. Int Arch Allergy Immunol (2010) 0.92
Animal models of asthma: Pro: Allergic avoidance of animal (model[s]) is not an option. Am J Respir Crit Care Med (2006) 0.87
Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res (2006) 2.43
PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2007) 1.74
Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene (2004) 1.50
Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair. Proc Am Thorac Soc (2005) 1.42
Constitutive activation of prosurvival signaling in alveolar mesenchymal cells isolated from patients with nonresolving acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2005) 1.23
Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist. J Biol Chem (2010) 1.14
PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia (2005) 1.14
Endothelial cell peroxisome proliferator-activated receptor γ reduces endotoxemic pulmonary inflammation and injury. J Immunol (2012) 1.04
Changes in weather and the effects on pediatric asthma exacerbations. Ann Allergy Asthma Immunol (2009) 1.04
Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury. Am J Physiol Lung Cell Mol Physiol (2010) 1.00
Down-regulated peroxisome proliferator-activated receptor γ (PPARγ) in lung epithelial cells promotes a PPARγ agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD). J Biol Chem (2013) 1.00
The nitrated fatty acid 10-nitro-oleate attenuates allergic airway disease. J Immunol (2013) 0.92
Effects of JAM-A deficiency or blocking antibodies on neutrophil migration and lung injury in a murine model of ALI. Am J Physiol Lung Cell Mol Physiol (2012) 0.90
Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma. Respir Res (2007) 0.88
Curcumin-loaded apotransferrin nanoparticles provide efficient cellular uptake and effectively inhibit HIV-1 replication in vitro. PLoS One (2011) 0.88
Age-specific factors influencing asthma management by older adults. Qual Health Res (2009) 0.86
Pulmonary administration of a water-soluble curcumin complex reduces severity of acute lung injury. Am J Respir Cell Mol Biol (2012) 0.85
Curcumin is not a ligand for peroxisome proliferator-activated receptor-γ Gene Ther Mol Biol (2009) 0.85
PPARs in alveolar macrophage biology. PPAR Res (2007) 0.85
The Nitrated Fatty Acid 10-Nitro-oleate Diminishes Severity of LPS-Induced Acute Lung Injury in Mice. PPAR Res (2012) 0.83
Stimulatory Effects of Peroxisome Proliferator-Activated Receptor-gamma on Fcgamma Receptor-Mediated Phagocytosis by Alveolar Macrophages. PPAR Res (2007) 0.82
Community-acquired methicillin-resistant Staphylococcus aureus pneumonia and ARDS: 1-year follow-up. Chest (2009) 0.81
Nrf2 and PPAR{gamma}: PPARtnering against oxidant-induced lung injury. Am J Respir Crit Care Med (2010) 0.79
Facile syntheses of acyl dihydroxyacetone phosphates and lysophosphatidic acids having different acyl groups. J Lipid Res (2006) 0.77
Simple, rapid, high-purity preparation of recombinant human platelet-derived growth factor-BB. Biotechnol Lett (2007) 0.77
Increased yield of high purity recombinant human interferon-gamma utilizing reversed phase column chromatography. Protein Expr Purif (2006) 0.75
Pediatric Dyspnea Scale for use in hospitalized patients with asthma. J Allergy Clin Immunol (2009) 0.75